Slide 1: TScan Therapeutics KOL event: Dec. 11, 2023
TScan Therapeutics KOL event: Dec. 11, 2023 Exhibit 99.2
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, prog
Slide 3: Presenters
Presenters Monzr M. Al Malki, M.D. Hematologist-Oncologist, City of Hope Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation Director, Unrelated Donor BMT Program Director, Haploidentical Transplant Program Gavin MacBeath, Ph.D. Chief Executive Of
Slide 4: TScan: A fully integrated, next-generation TCR-T cell company
TScan: A fully integrated, next-generation TCR-T cell company Rapid discovery of targets and TCRs Transposon-based T cell engineering Clinical-phase programs in heme and solid tumor malignancies Infectious disease Autoimmune disease Oncology Rapidly-growing oncology pipeline Broad therapeutic potent
Slide 5: Platform delivers broad proprietary pipeline
Platform delivers broad proprietary pipeline Primary solid tumor IND, T-Plex, supports simultaneous use of multiple TCRs HLA type Indications Programs (target) TSC-100 (HA-1) HLA-A*02:01 HLA-A*02:01 HLA-A*02:01 HLA-C*07:02 HLA-B*07:02 HLA-A*02:01 HLA-A*24:02 HLA-A*02:01 HLA-C*07:02 HLA-A*01:01 HLA-A
Slide 6: Heme malignancies: TCR-T candidates designed to treat residual disease and prevent relapse
Heme malignancies: TCR-T candidates designed to treat residual disease and prevent relapse in patients undergoing allogeneic HCT
Slide 7: Highlights of ASH presentation
Highlights of ASH presentation All six patients treated with TSC-100 or TSC-101 showed no evidence of relapse, with four patients on study for >6 months All six patients showed complete donor chimerism and no evidence of residual disease at every reading starting 3 weeks after their first dose One o
Slide 8: TCR-T has unique potential to address myeloid leukemias
TCR-T has unique potential to address myeloid leukemias Source: Independent KOL market research conducted June 2020. Heme malignancies AML, MDS, ALL that are not addressed by CAR-T therapy 35,000 cases/year US Allogeneic hematopoietic cell transplant (HCT) is considered curative for many and is expe
Slide 9: TSC-100/101 are designed to eliminate residual cancer cells and prevent relapse following HCT
TSC-100/101 are designed to eliminate residual cancer cells and prevent relapse following HCT Conditioning therapy PATIENT DONOR Hematopoietic cell transplant Stem cells CURE TCR T-cell therapy T cell HA-1 TCR Cancer cell Normal blood cell Stem cell T cell HA-1 positive HA-1 negative Residual cancer
Slide 10: Key biomarkers for residual leukemia or residual patient-derived blood cells
Key biomarkers for residual leukemia or residual patient-derived blood cells serve as potential early surrogates of efficacy Residual Leukemia (HA-1-positive) Residual blood cells (HA-1-positive) HA-1-negative donor blood cells Post-transplant Patient Donor Chimerism Minimal Residual Disease (MRD) M
Slide 11: Initial Results of a Phase 1 trial of TSC-100 and TSC-101
Initial Results of a Phase 1 trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation Abstract # 2090 Monzr Al Malki1, Alla Keyzner2, Hyung C. Suh3, Aasiya Matin4, Erica Buonomo5, Yu
Slide 12: Trial design and dose escalation
HA-2 positive (~40%) Transplant + TSC-101 HA-1 positive (~60%) Patient A*02:01 negative (~58% US pop) Transplant Transplant + TSC-100 Dose escalation has reached dose level 3 for TSC-100 & TSC-101 Patient A*02:01 positive (~42% US pop) AML, MDS, ALL: haploidentical donor transplant with reduced inte
Slide 13: Patient risk factors well-balanced between treatment and control arms
Dose Level 3 reached Patient risk factors well-balanced between treatment and control arms ‡ Dose did not meet target dose criteria, * scheduled dosing TSC-100 TSC-101 Control Arm Patient ID P-004-0004 P-007-0002 P-004- 0007 P-006- 0003 P-004-0001 P-004-0005 P-004-0006 P-004-0008 P-002-0001 P-007-00
Slide 14: Key biomarkers: donor chimerism assays
Key biomarkers for residual leukemia or residual patient-derived blood cells serve as potential early surrogates of efficacy Residual Leukemia (HA-1-positive) Residual blood cells (HA-1-positive) High sensitivity NGS-based Alloheme (~400 genes) Sensitivity ~0.13% Performed at CareDx Standard STR-bas
Slide 15: Complete donor chimerism achieved in 6/6 treated patients versus 0/4 control
Control patient #1 Control patient #2 Control patient #3 Control patient #4 Complete donor chimerism achieved and maintained in 6/6 (100%) treated patients versus 0/4 (0%) control patients Day post HCT TSC-100 DL 1 TSC-100 DL 2 TSC-100 DL 3 TSC-101 DL 1 TSC-101 DL 2-supp TSC-101 DL 2 Day 21/28 Day 4
Slide 16: Complete chimerism maintained >7 months in treated patients
Complete chimerism maintained >7 months in treated patients; Worsening chimerism and one relapse observed in control-arm patients RELAPSE Donor chimerism in CD3+ and CD33+ subsets Treatment arms Donor chimerism in CD3+ and CD33+ subsets Control arm
Slide 17: Key biomarkers: minimal residual disease
Key biomarkers for residual leukemia or residual patient-derived blood cells serve as potential early surrogates of efficacy Residual Leukemia (HA-1-positive) Residual blood cells (HA-1-positive) High sensitivity Next-gen sequencing Sensitivity ~0.1% Performed at Columbia University Standard Flow cy
Slide 18: All treated patients achieved MRD negativity & complete donor chimerism
All treated patients achieved MRD negativity & complete donor chimerism* *MRD and chimerism determined by NGS (lower limits of detection 0.05-0.1% and 0.13%, respectively) ‡ Dose did not meet target dose criteria in supplemental cohorts X X 0 100 200 300 400 MDS T-ALL AML AML B-ALL AML B-ALL MDS MDS
Slide 19: One AML patient converted from MRD-positive to MRD-negative following TSC-101
One AML patient converted from MRD-positive post-transplant to MRD-negative following treatment with TSC-101 P-004-0005 MRD+ AML TSC-101 Days MDS: myelodysplastic syndrome; RIC: reduced intensity conditioning; HCT: hematopoietic cell transplant; PTCy: post-transplant cyclophosphamide; MRD: minimum r
Slide 20: TSC-100 & TSC-101 persisted in peripheral circulation for over 200 days
TSC-100 & TSC-101 persisted in peripheral circulation for over 200 days Single dose cohorts Repeat dose cohorts All patients had detectable TSC-100 or TSC-101 TCR-T cells at all time points to date Repeat dosing resulted in increased levels of circulating TCR-T cells
Slide 21: Most frequent adverse events similar between treatment and control arms
Most frequent ≥ grade 2 adverse events* were similar between treatment and control arms Adverse event ≥Grade 2 TSC-100/ 101 arms Highest Grade# N=8 Control arm Highest Grade# N=4 Anemia 3 4 Abdominal Pain 2 2 Nausea/ vomiting 2 2 Diarrhea 3 2 Fatigue 2 2 Pyrexia 2 3 Pneumonia 2 3 ALT/ AST increased
Slide 22: Serious adverse events were similar between treatment and control arms
Serious adverse events were similar between treatment and control arms Arm Patient ID Serious Adverse Event Highest Grade* Post Transplant Day TSC Relatedness TSC-100-DL3 P-004-0007 Sepsis, respiratory failure 4 +9 Not applicable (pre-TSC) TSC-101-DL2supp P-004-0005 Pyrexia 1 +21 Not applicable (pre
Slide 23: Adverse events of special interest were similar between arms
Adverse events of special interest were similar between treatment and control arms Arm-Dose Level Patient ID Grade* Adverse Event Transplant Day of Onset Duration TSC relatedness TSC-100-DL2 P-007-0002 Grade 1 CRS +3 2 days Not applicable (pre-TSC) TSC-101- DL2supp P-004-0005 Grade 2 CRS +1 3 days N
Slide 24: Lab markers of CRS changed minimally after TSC-100 or TSC-101
Lab markers of CRS changed minimally after TSC-100 or TSC-101 administration No clinical CRS or neurotoxicity reported after TSC-100 or TSC-101 dosing C-reactive protein (CRP)
Slide 25: Very different outcomes observed for two patients with TP53-mutated MDS
Very different outcomes observed for two patients with TP53-mutated MDS *MRD and chimerism determined by NGS (lower limits of detection 0.1% and 0.13%, respectively) 0 100 200 300 400 MDS MDS Control-3 Disease Time (days post-transplant) Pre-HCT MRD RELAPSE MRD-positive TSC-101 dose MRD-negative Com
Slide 26: Summary and next steps
Summary and next steps Initial data look promising, with no relapses in treatment arms (median follow-up >6 months) TSC-100 and TSC-101 were generally well-tolerated, and the third and final dose level has been reached 10 clinical sites are currently enrolling patients We plan to open expansion coho
Slide 27: Questions and Answers
Questions and Answers
Slide 28: Potential near-term opportunity to address the unmet need for thousands of patients
Potential near-term opportunity to address the unmet need for thousands of patients Non-HLA A02 Non-Haplo US addressable market could triple with changes in transplant practice and double with additional HLAs and targets HCT: Hematopoietic Cell Transplant. MAC: Myeloablative Conditioning; MRD: Match
Slide 29: Long-term opportunities to address tens of thousands of patients globally
Long-term opportunities to address tens of thousands of patients globally in multiple indications Addressable patients with suite of TCRs Expansion to Europe Minimal conditioning Relapsed/ refractory rescue Non-malignant indications Source: SEER, CIBMTR, ClearView Analysis 0 25,000 20,000 15,000 Add